Sort
21,453 grants matching “tuberculosis”
Lesion-centric imaging and PK-PD of pyrazinamide for TB/HIV co-infection
$788,180Veronique Dartois · Rbhs-New Jersey Medical School · R01 · FY2016 · AI
THE COMPLETE GENOME SEQUENCE AND ANALYSIS OF M SMEGMATIS
$788,175Institute For Genomic Research · U01 · FY2000 · AI
De facto monotherapy during multidrug TB treatment and emergence of resistance
$788,126Veronique Dartois · Rbhs-New Jersey Medical School · R01 · FY2015 · AI
Inhalational therapy with spectinamides within new regimens of TB therapy
$788,086Mercedes Gonzalez-Juarrero · Colorado State University · R01 · FY2025 · AI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling
$787,916George Louis Drusano · Ordway Research Institute, Inc. · R01 · FY2008 · AI
Foam cells as drug targets in tuberculosis
$787,897Maria Laura Gennaro · Rbhs-New Jersey Medical School · R01 · FY2021 · HL
Trial of Metformin for TB/HIV Host-directed Therapy
$787,888Hardy Kornfeld · Univ Of Massachusetts Med Sch Worcester · U01 · FY2020 · AI
Structural Genomics of Persistence Targets from M. tuberculosis
$787,755James C Sacchettini · Texas A&M Agrilife Research · P01 · FY2009 · AI
National Tuberculosis Curriculum Consortium (NTCC)
$787,728Antonino None Catanzaro · University Of California, San Diego · N01 · FY2009 · HL
Foam cells as drug targets in tuberculosis
$787,457Maria Laura Gennaro · Rbhs-New Jersey Medical School · R01 · FY2020 · HL
Development of a Self Inactivating, Highly Effective TB Vaccine
$787,367Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI
Host Determinants of TB Disease Progression
$787,288Alan A Aderem · Seattle Biomedical Research Institute · U19 · FY2013 · AI
Tuberculosis Second Line Drug Susceptibility Chip
$787,280Eric R Houpt · University Of Virginia · R01 · FY2014 · AI
Tuberculosis Second Line Drug Susceptibility Chip
$787,280Eric R Houpt · University Of Virginia · R01 · FY2015 · AI
Tuberculosis Second Line Drug Susceptibility Chip
$787,280Eric R Houpt · University Of Virginia · R01 · FY2012 · AI
Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for Tuberculosis
$787,171Christina Leigh Stallings · Washington University · R01 · FY2024 · AI
Contribution of CD8 T cells in Controlling Tuberculosis
$787,116Philana Ling Lin · University Of Pittsburgh At Pittsburgh · R56 · FY2018 · AI
Foam cells as drug targets in tuberculosis
$787,112Maria Laura Gennaro · Rbhs-New Jersey Medical School · R01 · FY2022 · HL
Identifying Optimal Treatment Strategies for Tuberculosis Treatment
$786,787Radojka Savic · University Of California, San Francisco · R01 · FY2019 · AI
Molecular Genetic Analysis of Mycobacterium Tuberculosis
$786,783William Robert Jacobs · Albert Einstein College Of Medicine · R37 · FY2024 · AI
METABOLIC REPROGRAMMING OF T CELL ENERGY METABOLISM IN TUBERCULOSIS AND HIV
$786,706Adrie Jc Steyn · University Of Alabama At Birmingham · R33 · FY2021 · AI
PS05-003, TUBERCULOSIS CONTROL PROGRAM AND AIDS
$786,201James L Hadler · Connecticut State Dept Of Public Health · U52 · FY2007 · PS
De facto monotherapy during multidrug TB treatment and emergence of resistance
$786,135David Alland · Rbhs-New Jersey Medical School · R01 · FY2018 · AI
Preclinical modeling to study Tuberculous Meningitis
$786,130Sanjay Jain · Johns Hopkins University · R01 · FY2023 · AI
Development of a Self Inactivating, Highly Effective TB Vaccine
$786,054Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · AI